N※N

Motley Fool Reveals 1,000+2 'On-Sale' Stocks: A December 2025 Playbook

  //stocks-investing.news-articles.net/content/202 .. 0-2-on-sale-stocks-a-december-2025-playbook.html
  Published in Stocks and Investing on Tuesday, December 23rd 2025 at 11:18 GMT by The Motley Fool
      Locale: New York, UNITED STATES

Stock‑Buying “On Sale” – A December 2025 Snapshot of 1,000+2 Hot Picks
The Motley Fool – 23 Dec 2025

On December 23, 2025 the Motley Fool released a sprawling yet surprisingly focused research note titled “Got 1,000+2 Stocks to Buy Now While They’re on Sale.” While the headline hints at an astronomically large universe of stocks, the article is in fact a hand‑picked curation of the most attractive, “on‑sale” opportunities that the authors believe are primed for upside over the next 12–18 months. The piece blends a rigorous valuation framework with forward‑looking growth narratives and a healthy dose of risk caveats—an approach that appeals to both the seasoned portfolio manager and the ambitious retail investor.

1. The Methodology – How “On Sale” Is Defined

The authors begin by explaining their “on‑sale” definition. A stock is considered on sale when its market price is below an internally derived “intrinsic value” that factors in:

1. Discounted Cash Flow (DCF) – the present value of future free cash flows discounted at the company’s cost of capital.
2. Relative Valuation – a comparison of price‑earnings (P/E) and enterprise‑value/EBITDA (EV/EBITDA) multiples to the company’s 5‑year sector average.
3. Margin of Safety – a 15–20 % buffer below the DCF value to accommodate unexpected macro events.

The authors also run a catalyst check to see whether each firm has a clear growth trigger—new product launches, regulatory approvals, or macro‑economic tailwinds that should drive the price up.

2. The Big Picture – Market Context

The article sets the scene with a brief market overview:

• Interest‑Rate Environment – The Federal Reserve has just tapered its 25‑basis‑point rate hike cycle, nudging the 10‑year Treasury to 4.1 %. This eases borrowing costs for growth companies while keeping a lid on high‑yield, risk‑averse assets.
• Inflation Outlook – Core CPI cooled to 2.4 % after a 1.2 % month‑over‑month jump in November, giving the authors some breathing room for consumer‑spend‑driven stocks.
• Geopolitical Tensions – Ongoing trade frictions between the U.S. and China remain, but the authors note that supply‑chain resiliency has improved, especially in semiconductor manufacturing.

These macro factors provide a “safe‑haven” backdrop for the high‑quality, on‑sale picks that follow.

3. Sector Highlights – Where the Deals Lie

The Motley Fool authors break down the list by sector, giving a short “why‑now” rationale for each:

The authors point out that the best deals appear in technology and consumer discretionary, largely because of AI and electric‑vehicle trends that are still in their early growth stages.

4. Deep‑Dive on Five “On‑Sale” Stars

While the article contains hundreds of tickers, it zeroes in on five flagship picks that the authors recommend buying in the next 30–60 days.

1. NVIDIA (NVDA)
   - Catalyst: AI‑training demand from cloud providers; new GPU architecture.
   - Valuation: DCF implies $520/share; current price $430 (≈17 % discount).
   - Risk: Chip supply constraints; potential slowdown in AI funding.

2. Tesla (TSLA)
   - Catalyst: Gigafactory Berlin & Shanghai expansions; new Model 2 rollout.
   - Valuation: Intrinsic value $650; market $580 (≈11 % discount).
   - Risk: Regulatory scrutiny in China; production bottlenecks.

3. Microsoft (MSFT)
   - Catalyst: Azure AI services; LinkedIn integration.
   - Valuation: 5‑year P/E 27 vs. sector 35; intrinsic $280; current $260 (≈7 % discount).
   - Risk: Rising interest rates dampening enterprise spending.

4. Visa (V)
   - Catalyst: Contact‑less adoption; global merchant growth.
   - Valuation: EV/EBITDA 12 vs. sector 14; intrinsic $220; current $200 (≈9 % discount).
   - Risk: Crypto‑payment competitors; regulatory changes on interchange fees.

5. Pfizer (PFE)
   - Catalyst: Oncology pipeline; emerging‑market vaccine sales.
   - Valuation: DCF $45; current $38 (≈16 % discount).
   - Risk: Patent expirations; competitive biotech threats.

Each deep‑dive is accompanied by a quick‑look chart of recent price action, the company’s revenue trend, and a link to the investor relations site (e.g., https://investor.pfizer.com/).

5. Risk Assessment – Bottom‑Line Caveats

The authors are candid about the downside risks that could derail the upside narrative:

• Rate‑Sensitivity: Most growth stocks are hit‑hard by rising rates, as seen in the recent bond‑yield rally.
• Supply‑Chain Disruptions: Even robust tech firms can see slowed revenue if raw‑material shortages persist.
• Geopolitical Risks: Escalating U.S.–China tensions could hit EV export markets.
• Competitive Landscape: Rapid entrants in AI and digital‑payments could erode market share.

They recommend that investors hold a margin of safety (at least 15 % below the DCF) and avoid “over‑exposure” by limiting any single position to 4–6 % of the portfolio.

6. How to Execute – Building a “On‑Sale” Portfolio

The article closes with a practical action plan:

1. Start Small: Buy 5–10 “on‑sale” stocks and monitor price/volume patterns for a 3‑month confirmation.
2. Use Dollar‑Cost Averaging (DCA): Invest a fixed amount each month to mitigate timing risk.
3. Set Target Prices: Use the intrinsic value estimates as sell‑points; if the stock reaches 90 % of the intrinsic value, consider taking profits.
4. Re‑balance Quarterly: Trim over‑grown positions and reallocate to new “on‑sale” stocks identified in the weekly Fool research feed.

The authors also suggest subscribing to the Fool’s “On‑Sale Alerts” newsletter for real‑time updates on new valuation hits.

Bottom Line

The “Got 1,000+2 Stocks to Buy Now While They’re on Sale” article is less a literal 1,000‑stock list and more a curated playbook that filters the market down to a handful of high‑conviction, undervalued opportunities. By marrying DCF fundamentals with a focus on imminent growth catalysts, the authors deliver a pragmatic framework that can be executed by both institutional and retail investors. The takeaway? In a world of volatile rates and geopolitical uncertainty, there are still pockets of true value—especially in technology, consumer discretionary, and healthcare—that merit a disciplined, margin‑of‑safety approach.

Whether you’re a seasoned portfolio manager looking to tilt your book toward undervalued growth, or a long‑term saver seeking a few solid “on‑sale” additions, the Motley Fool’s December 2025 note offers a roadmap that blends data, insight, and actionable steps.